黄苦清心合剂治疗室性期前收缩阴虚火旺证的临床研究

Clinical study on Huangku Qingxin Mixture in the Treatment of Premature Ventricular Beat with Yin Deficiency and Fire Hyperactivity Syndrome

  • 摘要: 目的   观察黄苦清心合剂治疗室性期前收缩(PVB)阴虚火旺证患者的临床疗效及安全性。方法   选择符合诊断标准的PVB患者92例,采用随机数字法分为2组,对照组予以酒石酸美托洛尔治疗,治疗组在对照组的基础上加服黄苦清心合剂,疗程为8周。分析患者治疗前后中医证候积分、QT间期、校正的T波峰-末间期(Tp-ec间期)、心率变异性(HRV)及PVB次数的变化。结果   治疗组中医证候总有效率高于对照组(P<0.05)。治疗后2组QT间期、Tp-ec间期、HRV及PVB次数均较治疗前改善(P<0.01),治疗组优于对照组(P<0.05~0.01)。治疗期间治疗组未出现不良反应,对照组出现1例。结论   黄苦清心合剂可改善PVB阴虚火旺证患者的临床症状、降低中医证候积分和PVB次数、缩短QT间期和Tp-ec间期、改善HRV,有效治疗PVB阴虚火旺证并且安全性高。

     

    Abstract: OBJECTIVE  To observe the clinical efficacy and safety of Huangku Qingxin mixture in the treatment of premature ventricular beat (PVB) with yin deficiency and fire hyperactivity syndrome.METHODS   92 patients who met the diagnosis criteria of the PVB were enrolled and randomly divided into two groups. The control group was given metoprolol tartrate while the treatment group was additionally given Huangku Qingxin mixture. The course of the treatment was eight weeks. The changes of TCM syndrome score, QT interval, corrected Tpeak-to-Tend interval (TP-EC interval), heart rate variability (HRV) and the number of PVB before and after treatment were compared.RESULTS   The total effective rate of TCM syndromes in the treatment group was higher than that in the control group (P < 0.05). In terms of QT interval, TP-EC, HRV, and PVBs, both groups improved after treatment compared with before treatment (P < 0.01), and the treatment group was better than that of the control group (P < 0.05, 0.01). During the treatment, there was no adverse reaction in the treatment group, but one case in the control group.CONCLUSION  Huangku Qingxin mixture can improve the clinical symptoms of PVB patients with yin deficiency and fire hyperactivity syndrome, decrease TCM syndrome score and PVBs, shorten QT interval and TP-EC interval, improve HRV, and effectively treat PVB in yin deficiency and fire hyperactivity pattern with high safety.

     

/

返回文章
返回